|Last Price$79.12||Day Change (%)1.62%|
|Open Price$78.06||Day Change ($)1.26|
|Day Range78.05–79.63||52-Week Range76.67–111.11|
As of Fri 9/30/2016 5:15:00 PM | USD
Gilead Sciences Halts Test of Bowel Disease Treatment
UPDATE: Allergan is paying a stunning 500% premium to buy a clinical-stage biotech
UPDATE: At $300,000 a year, Sarepta's new drug is considered a steal
News Highlights: Top Equities Stories of the Day
Polycythemia Vera Pipeline Report 2016 - Review of 12 Companies & 15 Molecules - Research and Markets
Scientists Honored for Hep C Research
AHF: New UCLA Study Shows Gay Men on PrEP Are 45 Times More Likely to Contract Syphilis; 25 Times More Likely To Be Infected With Gonorrhea
StockInvestor editor Matt Coffina and senior biotech analyst Karen Andersen discuss Gilead's growing competitive advantages.
This ETF is a bargain for investors who want exposure to profitable companies with durable competitive advantages.